COMP <GO>
GYRE vs UNH // GROSS PROFIT MARGIN
Gyre Therapeutics Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: GYRE 6
— UNH 7
▲ GROSS PROFIT MARGIN LEADER: GYRE
LAST: $4.73 (+3.84%) • MKT CAP: $527.4M
gross-margins
95.40%
LAST: $400.44 (-1.60%) • MKT CAP: $359.43B
gross-margins
88.31%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GYRE VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GYRE | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 95.40% | 88.31% | +7.09 | GYRE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 25.40% | 12.38% | +13.02 | GYRE | /roic <GO> |
| EV/EBITDA & P/E Valuation | 53.3x | 15.3x | +38.03 | UNH | /valuation <GO> |
| Free Cash Flow Yield | -0.03% | 6.25% | -6.28 | UNH | /fcf-yield <GO> |
| Operating Margin | 9.90% | 5.32% | +4.58 | GYRE | /operating-margins <GO> |
| Net Profit Margin | 8.50% | 3.53% | +4.97 | GYRE | /net-margins <GO> |
| Revenue Growth (YoY) | 10.20% | 3.33% | +6.87 | GYRE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.29% | -2.29 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 14.33 | 3.09 | +11.24 | GYRE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 39.5 | 55.1 | -15.60 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 67.2x | 17.7x | +49.46 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $527.4M | $359.43B | -$358.91B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GYRE REV | UNH REV | GYRE GROSS % | UNH GROSS % | GYRE FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $116.6M | $447.57B | 95.4% | 88.7% | -$180.0K | $16.07B |
| FY 2024 | $105.8M | $400.28B | 96.3% | 88.3% | -$6.0M | $20.70B |
| FY 2023 | $113.5M | $371.62B | — | 89.6% | $25.9M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GYRE // BETA —
UNH // BETA 0.33